FindTrial
Sign In

Short-term infusion of remifentanil in percutaneous radiofrequency ablation of small hepatocellular carcinoma causes hyperalagesia after withdrawal

Short-term infusion of remifentanil in percutaneous radiofrequency ablation of small hepatocellular carcinoma causes hyperalagesia after withdrawal

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-12002092
Enrollment
Unknown
Registered
2012-03-11
Start date
2012-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

A:venuous continuous infusion remifentanil

Sponsors

Cancer Center, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with small hepatocellular carcinoma; 2. Patients undergoing percutaneous radiofrequency ablation.

Exclusion criteria

Exclusion criteria: 1. small hepatocellular carcinoma located in the surface of liver; 2. patients with unsatisfactory analgesia.

Design outcomes

Primary

MeasureTime frame
VAS;side effect;—

Countries

China

Contacts

Public ContactZeng weian
zengwa@sysucc.org.cn+86 20 87343060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026